BMY

Bristol Myers Squibb (BMY) declined 2.41% on October 23, 2026, outpacing the broader market's 0.52% loss. The biopharmaceutical company is set to report earnings on October 29, 2026, with forecasted EPS of $1.28 (down 21.47% year-over-year) and revenue of $12.56 billion (up 2.75%). BMY trades at a Forward P/E of 9.61, below its industry average, and holds a Zacks Rank of #3 (Hold) with recent EPS estimate revisions trending downward by 5.69% over the past month.

Bristol Myers Squibb (BMY) is recommended over AbbVie (ABBV) despite ABBV's stronger revenue and earnings growth. BMY trades at a significant valuation discount (9.68X vs 18.21X forward earnings), offers a higher dividend yield (4% vs 2.43%), and has a better Zacks Rank (#3 Hold vs #4 Sell). However, BMY faces challenges from legacy drug erosion and elevated debt levels, while ABBV benefits from strong Skyrizi and Rinvoq growth but faces intensifying competition and downward earnings revisions.

Bristol Myers Squibb demonstrates steadier year-over-year revenue growth with consistent upward trends, while Pfizer shows higher absolute revenue but experienced recent fluctuations and contraction periods. BMY's revenue is projected to edge up 3% to $49.9 billion with net income rising over 40%, while PFE's revenue is expected to slump slightly to $62.2 billion despite net income gains. Based on revenue trends alone, Bristol Myers Squibb appears to be on a better trajectory, though both companies show positive comparable quarter-over-quarter growth.

Bristol Myers Squibb's legacy drug portfolio declined 5% in H1 2026 due to generic competition, though Eliquis showed strong 19% growth. The company raised 2026 revenue guidance but faces significant headwinds in 2027 with expected Eliquis sales decline of $1.5-$2 billion and upcoming generic competition in 2028. BMY must rely on its Growth Portfolio to offset legacy product pressures.

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

Bristol Myers Squibb (BMY) has been a trending stock but faces headwinds with shares down 11.1% over the past month. While the company maintains a Zacks Rank #3 (Hold) rating and trades at a valuation discount to peers, earnings estimates have declined 3.6% over the last 30 days. The company has a strong track record of beating consensus estimates but faces modest revenue growth projections of 3.4% for the current fiscal year.

Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles.

Bristol Myers Squibb (BMY) closed down 2.58% to $57.60, underperforming the S&P 500. The company is set to report earnings on October 29, 2026, with projected EPS of $1.56 (down 4.29% YoY) and revenue of $12.54 billion (up 2.59% YoY). BMY trades at a Forward P/E of 8.7, below its industry average of 23.43, and holds a Zacks Rank #3 (Hold) rating with recent downward estimate revisions.

Bristol Myers Squibb (BMY) has outperformed the S&P 500 with a 35.8% gain over the past year, driven by strong performance from its Growth Portfolio including Opdivo Qvantig, Reblozyl, Camzyos, and Breyanzi. Recent FDA approvals like Zenbexus and positive pipeline progress offer long-term growth potential.

However, the legacy portfolio faces continued generic competition, and much of the near-term optimism appears reflected in current valuations. Analysts recommend a cautious stance with a Hold rating.

Bristol Myers Squibb (BMY) has demonstrated a strong track record of beating earnings estimates, with an average beat of 19.01% over the last two quarters. The company has a positive Earnings ESP of +1.12% and a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in its next report expected on October 29, 2026. Stocks with positive Earnings ESP and Zacks Rank #3 or better historically beat consensus estimates nearly 70% of the time.

The article recommends two high-yield stocks for October: Bristol Myers Squibb (BMY) offering a 4.2% dividend yield despite facing near-term patent expiration challenges, and Realty Income (O) with a 6% yield and 31-year dividend increase streak, though facing headwinds from rising interest rates. Both stocks are trading at attractive valuations due to short-term concerns, presenting opportunities for long-term income-focused investors.

Bristol Myers Squibb (BMY) is highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of B. The company, a leading specialty biopharmaceutical firm, benefits from its blockbuster immuno-oncology drug Opdivo and efforts to revive its portfolio. With an attractive forward P/E ratio of 8.63 and recent positive earnings estimate revisions, BMY is recommended for value-focused investors.

Dollar General, Bristol-Myers Squibb, and Equinor ASA have received broker rating upgrades despite macroeconomic headwinds. All three stocks show positive earnings growth expectations and improved analyst sentiment, with Equinor showing the strongest projected earnings growth at 120.7% year-over-year.

Bristol Myers Squibb (BMY) is identified as a compelling value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company's valuation metrics, including a P/S ratio of 2.54 (below industry average of 6.12) and P/CF ratio of 7.95 (below industry average of 11.40), suggest the stock is undervalued relative to its earnings outlook.

Bristol Myers Squibb (BMY) is receiving significant investor attention. The stock has declined 6.1% over the past month, underperforming the S&P 500.

However, the company maintains a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions and strong recent performance, with the stock trading at a valuation discount to peers. BMY beat consensus estimates in the last four quarters with an EPS surprise of +28.3% and revenue surprise of +11.15%.

The article compares two pharmaceutical giants with divergent strategies: Bristol Myers Squibb, a deep-value dividend payer trading at cheap multiples (P/E 14.07) with flat revenue but stabilizing earnings, versus Eli Lilly, a high-growth juggernaut riding explosive success in GLP-1 metabolic drugs with 45% revenue growth and a P/E of 40.26. Despite BMY's attractive valuation, the author recommends LLY for 2026 due to its strong growth trajectory, successful drug pipeline including Retatrutide and lipoprotein(a) therapeutics, and forecast for 30% revenue growth.

Pfizer offers a higher dividend yield of 5.8% compared to Bristol Myers Squibb's 4.3%, making it more attractive for income investors. However, Bristol Myers Squibb maintains a safer dividend with a 55% payout ratio versus Pfizer's over 100% payout ratio.

Both pharma companies face patent cliffs but have growth prospects. The article suggests Pfizer is better for maximizing income, while Bristol Myers Squibb may deliver higher total returns due to lower execution risk.

Bristol Myers Squibb has demonstrated more stable and consistent revenue growth over the past two years, leading in seven of eight quarters. Novo Nordisk experienced significant volatility, with a dramatic 32% revenue spike in Q1 2026 following its Wegovy weight-loss pill launch, but faced sequential declines in Q2 2026 due to pricing pressure and ordering patterns. While Novo Nordisk's GLP-1 portfolio drives investor interest, its heavy dependence on Ozempic and Wegovy (70% of sales) presents concentration risk compared to Bristol Myers Squibb's more diversified growth portfolio.

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR.

North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

An investment analyst discusses their strategy with Eli Lilly stock, highlighting the pharmaceutical industry's business growth and robust pipeline of new treatments. The article emphasizes the diversification benefits of pharmaceutical stocks due to their lower correlation with the broader economy.